UMIN-CTR Clinical Trial

Basic information
Public title	Tests on satiety
Acronym	Tests on satiety
Scientific Title	Tests on satiety
Scientific Title:Acronym	Tests on satiety
Region	Japan

Condition
Condition	None
Classification by specialty	Not applicable Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To preliminarily confirm the effect of satiety on the consumption of the test food in healthy adult males by a randomized, double-blind, placebo-controlled, crossover comparative study.
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Satiety VAS
Key secondary outcomes	Dietary intake (dietary intake group only)

Base
Study type	Interventional

Study design
Basic design	Cross-over
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	2
Purpose of intervention	Prevention
Type of intervention	Food
Interventions/Control_1	Single intake of test food
Interventions/Control_2	Single intake of placebo food
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	60 years-old >
Gender	Male
Key inclusion criteria	1) Japanese males between the ages of 20 and 60 years old at the time consent is obtained. 2) Persons with no abnormal blood glucose levels (those who have never had abnormal blood glucose levels indicated in a medical checkup) 3) Persons with a BMI between 18.5 kg/m2 and 22.0 kg/m2 4) Persons who have received a full explanation of the purpose and content of the study and who have signed a consent form prior to the start of the study.
Key exclusion criteria	1) Those who have a history or current condition (disease) of liver disease, renal disease, cerebrovascular disease, diabetes, dyslipidemia, hypertension, or other chronic diseases. 2) Those who are currently undergoing treatment for a serious illness. 3) Persons with food allergies or those who may develop allergies related to the tested food items. 4) Persons who regularly use medicines or quasi-drugs that may affect the test items. 5) Persons who regularly use health foods (food for specified health use, nutritional supplements, functional foods, supplements, etc.) that may affect the test items. 6) Those who are unable to discontinue the intake of pharmaceuticals (excluding intravenous medication), quasi-drugs, or health foods (food for specified health uses, nutritional supplements, foods with functional claims, supplements, etc.) from the time of obtaining consent to the completion of the study. 7) Those whose lifestyle is extremely irregular (e.g., working at night or living day and night in reverse) 8)Persons who are unable to maintain their daily lifestyle (e.g., exercise and drinking habits) 9) Persons who have difficulty consuming the test food as directed. 10) Other subjects who are judged by the investigator to be unsuitable for the study.
Target sample size	22

Research contact person
Name of lead principal investigator	1st name Masahiko Middle name Last name Nakamura
Organization	Medical Corporation Ouryokukai Nihonbashi Sakura Clinic
Division name	department of internal medicine
Zip code	103-0025
Address	1-9-2 Nihonbashikayabacho, Chuo-ku, Tokyo
TEL	0366619061
Email	mail-1@ouryokukai.sakura.ne.jp

Public contact
Name of contact person	1st name Masako Middle name Last name Mizuuchi
Organization	APO PLUS STATION CO., LTD.
Division name	Clinical Operation Department, CRO Business Division
Zip code	103-0027
Address	2-14-1,Nihonbashi,Chuo-ku,Tokyo, Japan
TEL	03-6386-8809
Homepage URL
Email	food-contact@apoplus.co.jp

Sponsor
Institute	APO PLUS STATION CO., LTD.
Institute
Department

Funding Source
Organization	ANGFA Co.,Ltd.
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization	Institutional Review Board,Medical Corporation Ouryokukai Nihonbashi Sakura Clinic
Address	1-9-2 Nihonbashikayabacho, Chuo-ku, Tokyo
Tel	03-6661-9061
Email	c-irb_ug@neues.co.jp

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2022 Year 05 Month 06 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Open public recruiting
Date of protocol fixation	2022 Year 04 Month 26 Day
Date of IRB	2022 Year 04 Month 26 Day
Anticipated trial start date	2022 Year 05 Month 07 Day
Last follow-up date	2022 Year 06 Month 25 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date	2022 Year 05 Month 06 Day
Last modified on	2022 Year 05 Month 07 Day

Link to view the page
URL(English)	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054324

Research Plan
Registered date	File name

Research case data specifications
Registered date	File name

Research case data
Registered date	File name

Contact us.